1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 121 pages

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016’, provides an overview of the B-Cell Chronic Lymphocytic Leukemia pipeline landscape.

The report provides comprehensive information on the therapeutics under development for B-Cell Chronic Lymphocytic Leukemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for B-Cell Chronic Lymphocytic Leukemia and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of B-Cell Chronic Lymphocytic Leukemia
- The report reviews pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved B-Cell Chronic Lymphocytic Leukemia therapeutics and enlists all their major and minor projects
- The report assesses B-Cell Chronic Lymphocytic Leukemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for B-Cell Chronic Lymphocytic Leukemia

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
B-Cell Chronic Lymphocytic Leukemia Overview 9
Therapeutics Development 10
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Overview 10
Pipeline Products for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis 11
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Development by Companies 12
B-Cell Chronic Lymphocytic Leukemia - Therapeutics under Investigation by Universities/Institutes 14
B-Cell Chronic Lymphocytic Leukemia - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
B-Cell Chronic Lymphocytic Leukemia - Products under Development by Companies 18
B-Cell Chronic Lymphocytic Leukemia - Products under Investigation by Universities/Institutes 20
B-Cell Chronic Lymphocytic Leukemia - Companies Involved in Therapeutics Development 21
AB Science SA 21
Amgen Inc. 22
Celgene Corporation 23
Dynavax Technologies Corporation 24
Eisai Co., Ltd. 25
Elsalys Biotech SAS 26
F. Hoffmann-La Roche Ltd. 27
iDD biotech SAS 28
Immunomedics, Inc. 29
Johnson and Johnson 30
Juno Therapeutics Inc. 31
Molecular Templates Inc. 32
Noxxon Pharma AG 33
Ono Pharmaceutical Co., Ltd. 34
Regeneron Pharmaceuticals, Inc. 35
TheraMAB LLC 36
Unum Therapeutics, Inc. 37
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
202-b - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
AB-8779 - Drug Profile 49
Product Description 49
Mechanism of Action 49
RandD Progress 49
alemtuzumab biosimilar - Drug Profile 50
Product Description 50
Mechanism of Action 50
RandD Progress 50
AMG-319 - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
ATTCK-20 - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
Cellular Immunotherapy for Hematological Malignancies - Drug Profile 54
Product Description 54
Mechanism of Action 54
RandD Progress 54
Cellular Immunotherapy to Activate 4-1BBL and to Target CD19 for B-Cell Malignancies - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
Cellular Immunotherapy to Activate CD40L and to Target CD19 for B-Cell Malignancies - Drug Profile 56
Product Description 56
Mechanism of Action 56
RandD Progress 56
Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
Cellular Immunotherapy to Target CD16 for B-Cell Non-Hodgkin Lymphoma and B-Cell Chronic Lymphocytic Leukemia - Drug Profile 58
Product Description 58
Mechanism of Action 58
RandD Progress 58
Cellular Immunotherapy to Target CD19 for B-Cell Chronic Lymphocytic Leukemia - Drug Profile 59
Product Description 59
Mechanism of Action 59
RandD Progress 59
Cellular Immunotherapy to Target CD19 for B-Cell Malignancies - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
Cellular Immunotherapy to Target CD19 for Cancer - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
Cellular Immunotherapy to Target CD19 for Oncology - Drug Profile 62
Product Description 62
Mechanism of Action 62
RandD Progress 62
E-7449 - Drug Profile 63
Product Description 63
Mechanism of Action 63
RandD Progress 63
IDD-001 - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
IDD-002 - Drug Profile 66
Product Description 66
Mechanism of Action 66
RandD Progress 66
JNJ-64052781 - Drug Profile 67
Product Description 67
Mechanism of Action 67
RandD Progress 67
lenalidomide - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
MAT-303 - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
MT-3724 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
olaptesed pegol - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
ONO-4059 - Drug Profile 79
Product Description 79
Mechanism of Action 79
RandD Progress 79
REGN-1979 - Drug Profile 81
Product Description 81
Mechanism of Action 81
RandD Progress 81
SD-101 - Drug Profile 82
Product Description 82
Mechanism of Action 82
RandD Progress 82
TAB-08 - Drug Profile 84
Product Description 84
Mechanism of Action 84
RandD Progress 84
tocilizumab - Drug Profile 86
Product Description 86
Mechanism of Action 86
RandD Progress 86
B-Cell Chronic Lymphocytic Leukemia - Recent Pipeline Updates 90
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects 114
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products 117
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 118
Featured News and Press Releases 118
Apr 06, 2015: Juno Therapeutics Announces Patent Litigation Settlement 118
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 118
Appendix 120
Methodology 120
Coverage 120
Secondary Research 120
Primary Research 120
Expert Panel Validation 120
Contact Us 120
Disclaimer 121

List of Tables
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2016 10
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 13
Number of Products under Investigation by Universities/Institutes, H1 2016 14
Comparative Analysis by Late Stage Development, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Development by Companies, H1 2016 (Contd..1) 19
Products under Investigation by Universities/Institutes, H1 2016 20
B-Cell Chronic Lymphocytic Leukemia - Pipeline by AB Science SA, H1 2016 21
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Amgen Inc., H1 2016 22
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Celgene Corporation, H1 2016 23
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Dynavax Technologies Corporation, H1 2016 24
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Eisai Co., Ltd., H1 2016 25
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Elsalys Biotech SAS, H1 2016 26
B-Cell Chronic Lymphocytic Leukemia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 27
B-Cell Chronic Lymphocytic Leukemia - Pipeline by iDD biotech SAS, H1 2016 28
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Immunomedics, Inc., H1 2016 29
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Johnson and Johnson, H1 2016 30
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Juno Therapeutics Inc., H1 2016 31
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Molecular Templates Inc., H1 2016 32
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Noxxon Pharma AG, H1 2016 33
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 34
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 35
B-Cell Chronic Lymphocytic Leukemia - Pipeline by TheraMAB LLC, H1 2016 36
B-Cell Chronic Lymphocytic Leukemia - Pipeline by Unum Therapeutics, Inc., H1 2016 37
Assessment by Monotherapy Products, H1 2016 38
Number of Products by Stage and Target, H1 2016 40
Number of Products by Stage and Mechanism of Action, H1 2016 42
Number of Products by Stage and Route of Administration, H1 2016 44
Number of Products by Stage and Molecule Type, H1 2016 46
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Recent Pipeline Updates, H1 2016 90
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects, H1 2016 114
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..1), H1 2016 115
B-Cell Chronic Lymphocytic Leukemia - Dormant Projects (Contd..2), H1 2016 116
B-Cell Chronic Lymphocytic Leukemia - Discontinued Products, H1 2016 117

List of Figures
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H1 2016 10
Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 17
Assessment by Monotherapy Products, H1 2016 38
Number of Products by Top 10 Targets, H1 2016 39
Number of Products by Stage and Top 10 Targets, H1 2016 39
Number of Products by Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 41
Number of Products by Routes of Administration, H1 2016 43
Number of Products by Stage and Routes of Administration, H1 2016 43
Number of Products by Molecule Types, H1 2016 45
Number of Products by Stage and Molecule Types, H1 2016 45

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Myelocytic Leukemia (CML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the ...

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market  Forecast-2023

Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Acute Myeloid Leukemia (AML) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

Chronic lymphocytic leukemia- Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic lymphocytic leukemia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.